Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 14/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167854 | 0.84 | L3MBTL1 (0.64) | L3MBTL1SCN9ANPY5R | |
| SCHEMBL17055466 | 0.84 | MALT1 (0.53) | L3MBTL1SCN9AALDH1A1POLBNPY5R | |
| SCHEMBL4495998 | 0.82 | RXFP1 (0.48) | ALDH1A1POLB | |
| SCHEMBL17055469 | 0.78 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1POLB | |
| SCHEMBL20788239 | 0.77 | L3MBTL1 (0.56) | L3MBTL1SCN9ANPY5R | |
| SCHEMBL20788407 | 0.76 | L3MBTL1 (0.54) | L3MBTL1SCN9ACYP2C9CYP3A4CYP2D6 | |
| SCHEMBL31518946 | 0.76 | L3MBTL1 (0.69) | L3MBTL1SCN9AALDH1A1 | |
| SCHEMBL13710646 | 0.75 | SCN9A (0.76) | SCN9ACYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4058019 | 0.75 | SCN9A (0.64) | L3MBTL1SCN9ACYP2C9CYP3A4CYP2D6 | |
| Potassium Ion SCHEMBL7190441 | 0.74 | RIPK1 (0.51) | L3MBTL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1615895-A4 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| EP-1615895-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092140-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | L3MBTL1 3736/4885SCN9A 78/4885CYP2C9 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.